These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 24408121

  • 21. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
    Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S.
    Nephrol Dial Transplant; 2009 Jan; 24(1):156-60. PubMed ID: 18685141
    [Abstract] [Full Text] [Related]

  • 22. Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
    Dattolo PC, Gallo P, Michelassi S, Paudice N, Cannavò R, Romoli E, Fani F, Tsalouchos A, Mehmetaj A, Ferro G, Sisca S, Pizzarelli F.
    J Nephrol; 2016 Dec; 29(6):809-815. PubMed ID: 27015900
    [Abstract] [Full Text] [Related]

  • 23. Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.
    Chen J, Liu S, Xu H, Wang W, Xie Y, Tang W, Yuan Q, Zheng L, Lin L, Fu S, Shen J.
    Med Sci Monit; 2020 Aug 21; 26():e922839. PubMed ID: 32822333
    [Abstract] [Full Text] [Related]

  • 24. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
    Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Wheeler D, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Wang HY, Perkovic V, TESTING Study Group.
    JAMA; 2017 Aug 01; 318(5):432-442. PubMed ID: 28763548
    [Abstract] [Full Text] [Related]

  • 25. The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience.
    He WJ, Wang J, Liu N, Li GY, Zhu XW, Yao L, Liu LL.
    J Nephrol; 2024 May 01; 37(4):933-940. PubMed ID: 38225440
    [Abstract] [Full Text] [Related]

  • 26. Long-term results of a randomized controlled trial in childhood IgA nephropathy.
    Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, Hataya H, Honda M, Iijima K, Yoshikawa N, Japanese Pediatric IgA Nephropathy Treatment Study Group.
    Clin J Am Soc Nephrol; 2011 Jun 01; 6(6):1301-7. PubMed ID: 21493743
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V, DUPRO steering committee and PROTECT Investigators.
    Lancet; 2023 Dec 02; 402(10417):2077-2090. PubMed ID: 37931634
    [Abstract] [Full Text] [Related]

  • 28. Clinical Implications of C2 Lesion in IgA Nephropathy: A Cohort Study.
    Wang Z, Zhou X, Shi S, Liu L, Lv J, Zhang H.
    Am J Nephrol; 2024 Dec 02; 55(5):529-538. PubMed ID: 39074466
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov 02; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Urinary N-acetyl-β-glucosaminidase and estimated Glomerular filtration rate may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy.
    Bazzi C, Usui T, Rizza V, Casellato D, Gallieni M, Nangaku M.
    Nephrology (Carlton); 2018 Feb 02; 23(2):175-182. PubMed ID: 27764902
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy.
    Canney M, Barbour SJ, Zheng Y, Coppo R, Zhang H, Liu ZH, Matsuzaki K, Suzuki Y, Katafuchi R, Reich HN, Cattran D, International IgA Nephropathy Network, International IgA Nephropathy Network Investigators.
    J Am Soc Nephrol; 2021 Feb 02; 32(2):436-447. PubMed ID: 33514642
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H.
    Am J Kidney Dis; 2019 Jul 02; 74(1):15-22. PubMed ID: 30922594
    [Abstract] [Full Text] [Related]

  • 39. High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease.
    Xie D, Hou FF, Fu BL, Zhang X, Liang M.
    J Clin Pharmacol; 2011 Jul 02; 51(7):1025-34. PubMed ID: 20978279
    [Abstract] [Full Text] [Related]

  • 40. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.
    Yu MY, Kim YC, Koo HS, Chin HJ.
    PLoS One; 2017 Jul 02; 12(11):e0188375. PubMed ID: 29155873
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.